Redeye updates its estimates and valuation following MedCap’s Q2 2026 report, a broad-based beat versus our estimates on both sales and prof...
Redeye provides its initial take on MedCap’s Q2 2026 report, which came in well above our estimates on both sales and profitability.
Redeye updates its estimates and valuation following MedCap’s Q1 2026 report.
Redeye provides its initial take on MedCap’s Q1 2026 report, which came in broadly in line with our estimates for adjusted EBITA, though rev...
Redeye updates its estimates and valuation following MedCap’s Q4 2025 report.
Redeye provides its initial take on MedCap’s Q4 2025 report, which came in broadly in line with our estimates, with a slight beat in revenue...
Redeye updates its estimates and valuation following MedCap’s Q3 2025 report.
Redeye provides its initial take on MedCap’s Q3 2025 report, which came in broadly above our estimates.
Redeye updates its estimates and valuation following MedCap’s Q2 2025 report.
Redeye provides its initial take on MedCap’s Q2 2025 report, which roughly matched our top-line projection and beat our adjusted EBITA estim...
Redeye updates its estimates and valuation following MedCap releasing its Q1 2025 report.
Redeye provides its initial take on MedCap’s Q1 2025 report, which broadly aligned with our estimates.
Redeye updates its estimates and valuation following MedCap releasing its Q4 2024 report.
Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial estimates and in line with the company’...
Redeye briefly comments on MedCap releasing preliminary Q4 2024 figures, significantly undershooting our estimates, especially at the EBITA ...
Redeye initiates coverage of MedCap, a serial acquirer of niche life science SMEs that has posted strong organic growth, acquired growth, an...
Medcap reported a better Q2 versus our estimates, attributable to a strong performance in the Medtech segment with Abilia showing a robust r...
